Bli medlem
Bli medlem

Du är här


FIT Biotech Oy: Changes in FIT Biotech's Management team and Board of Directors

FIT Biotech Oy

Company Release January 21, 2016 at 8.30 EET

Changes in FIT Biotech's Management team and Board of Directors

Mr Andres Männik (43), Ph.D. has been appointed as Chief Scientific Officer
and member of Management Team of the Finnish biotechnology company FIT
Biotech as of January 20, 2016. Mr Männik has been employed by FIT Biotech
earlier in 2000-2011 as Senior Scientist specializing in GTU-technology.
Since 2011, Mr Männik has been employed by Estonian Icosagen Cell Factory OÜ
that used to be associated company of FIT Biotech. The current Chief
Scientific Officer, Professor Mart Ustav will continue his valued work with
the company as a member of the Scientific Advisory Board.

The Chairman of the Board of Directors of FIT Biotech Oy, Mr Rabbe Slätis has
been acting also as the CEO of the company since January 1, 2016 when Mr
Kalevi Reijonen retired from the position. Mr Slätis will now withdraw from
the position of the Chairman of the Board and will continue as board member.
Mr Juha Vapaavuori, M.Sc., Vice Chairman of the Board will act as Chairman of
the Board as of January 20, 2016.


Board of Directors

Further information:
Rabbe Slätis
CEO, FIT Biotech Oy
Tel: +358 (0) 40 840 6749

Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790

FIT Biotech Oy in brief:
FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA
vaccines and gene therapy. The company bases its products on its patented
GTU® (Gene Transport Unit) technology.

Through GTU® technology, FIT Biotech develops DNA-based therapeutics in order
to both prevent and also treat various diseases. Identified application areas
include HIV, tuberculosis (and other infectious diseases) as well as gene
therapy (cancer, autoimmune diseases). Other application areas are under

FIT Biotech Oy is listed on NASDAQ First North (ticker: FITBIO). More
information can be found at
Principal media


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FIT Biotech Oy via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.